WT1-specific CD8 + cytotoxic T cells with the capacity for antigen-specific expansion accumulate in the bone marrow in MDS

Suwabe, Tatsuya; Shibasaki, Yasuhiko; Sato, Hiroyuki; Tamura, Suguru; Katagiri, Takayuki; Nemoto, Hiroyuki; Kasami, Takuya; Kozakai, Takashi; Nanba, Ayako; Kitajima, Toshiki; Fuse, Kyoko; Ushiki, Takashi; Sone, Hirohito; Narita, Miwako; Masuko, Masayoshi

doi:10.1007/s12185-021-03083-0

Cited by 2 publications

(1 citation statement)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The tumor antigen Wilms’ tumor gene 1 (WT1) is expressed in MDS patients [ 107 ]. The presence of WT1-specific CD8 + T cells is observed in the BM of MDS patients [ 108 ]. Phase I clinical trials of vaccination with WT1 are safe and well tolerated and demonstrate the induction of a tumor-specific CD8 + T-cell response in MDS patients [ 109 , 110 ].…”

Section: Abnormal Immune Cell Repartition And/or Functions During The...mentioning

confidence: 99%

Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications

Simoni

Chapuis

2022

Diagnostics

View full text Add to dashboard Cite

Myelodysplastic syndromes (MDS) constitute a very heterogeneous group of diseases with a high prevalence in elderly patients and a propensity for progression to acute myeloid leukemia. The complexity of these hematopoietic malignancies is revealed by the multiple recurrent somatic mutations involved in MDS pathogenesis and the paradoxical common phenotype observed in these patients characterized by ineffective hematopoiesis and cytopenia. In the context of population aging, the incidence of MDS will strongly increase in the future. Thus, precise diagnosis and evaluation of the progression risk of these diseases are imperative to adapt the treatment. Dysregulations of both innate and adaptive immune systems are frequently detected in MDS patients, and their critical role in MDS pathogenesis is now commonly accepted. However, different immune dysregulations and/or dysfunctions can be dynamically observed during the course of the disease. Monitoring the immune system therefore represents a new attractive tool for a more precise characterization of MDS at diagnosis and for identifying patients who may benefit from immunotherapy. We review here the current knowledge of the critical role of immune dysfunctions in both MDS and MDS precursor conditions and discuss the opportunities offered by the detection of these dysregulations for patient stratification.

show abstract

Section: Abnormal Immune Cell Repartition And/or Functions During The...mentioning

confidence: 99%

Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications

Simoni

Chapuis

2022

Diagnostics

View full text Add to dashboard Cite

show abstract

Immune‐monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium

Tentori,

Zhao,

Tinterri

et al. 2024

HemaSphere

View full text Add to dashboard Cite

Advancements in comprehending myelodysplastic neoplasms (MDS) have unfolded significantly in recent years, elucidating a myriad of cellular and molecular underpinnings integral to disease progression. While molecular inclusions into prognostic models have substantively advanced risk stratification, recent revelations have emphasized the pivotal role of immune dysregulation within the bone marrow milieu during MDS evolution. Nonetheless, immunotherapy for MDS has not experienced breakthroughs seen in other malignancies, partly attributable to the absence of an immune classification that could stratify patients toward optimally targeted immunotherapeutic approaches. A pivotal obstacle to establishing “immune classes” among MDS patients is the absence of validated accepted immune panels suitable for routine application in clinical laboratories. In response, we formed International Integrative Innovative Immunology for MDS (i4MDS), a consortium of multidisciplinary experts, and created the following recommendations for standardized methodologies to monitor immune responses in MDS. A central goal of i4MDS is the development of an immune score that could be incorporated into current clinical risk stratification models. This position paper first consolidates current knowledge on MDS immunology. Subsequently, in collaboration with clinical and laboratory specialists, we introduce flow cytometry panels and cytokine assays, meticulously devised for clinical laboratories, aiming to monitor the immune status of MDS patients, evaluating both immune fitness and identifying potential immune “risk factors.” By amalgamating this immunological characterization data and molecular data, we aim to enhance patient stratification, identify predictive markers for treatment responsiveness, and accelerate the development of systems immunology tools and innovative immunotherapies.

show abstract

WT1-specific CD8 + cytotoxic T cells with the capacity for antigen-specific expansion accumulate in the bone marrow in MDS

Cited by 2 publications

References 50 publications

Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications

Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications

Immune‐monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium

Contact Info

Product

Resources

About